A. baumannii were tested for resistance to imipenem (10 µg), amikacin (30 µg), ciprofloxacin (5 µg) and ceftazidime (30 µg). Imipenem, amikacin and ciprofloxacin testing were according to EUCAST guidelines for A. baumannii [13]. The ceftazidime susceptibilities were interpreted using breakpoints according to CLSI guidelines for A. baumannii [14].
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.